There is no registration fee for this event. For the in-person symposium in Orlando, preregistration is required as seating is limited.
Faculty Harry Paul Erba, MD, PhD
Director, Leukemia Program
Professor in the Department of Medicine
Member of the Duke Cancer Institute
Duke University School of Medicine
Durham, North Carolina
Amir Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Tara L Lin, MD, MS
Professor, Hematologic Malignancies and Cellular Therapeutics
University of Kansas Medical Center
Kansas City, Kansas
Alexander Perl, MD
Associate Professor of Medicine
Perelman School of Medicine
Member, Leukemia Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Eytan M Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Moderator Neil Love, MD
Research To Practice
Miami, Florida
This activity is supported by educational grants from AbbVie Inc, Astellas, Daiichi Sankyo Inc, Kura Oncology, and Rigel Pharmaceuticals Inc.
Program Schedule — Eastern Time
7:00 AM – 7:30 AM — Registration and Breakfast
7:30 AM – 9:30 AM — Educational Meeting
MODULE 1: Up-Front Therapy for Older Patients with Acute Myeloid Leukemia (AML) — Dr Lin
Factors, such as patient age, performance status, medical history and cytogenetic risk profile, influencing the selection of treatment for newly diagnosed AML
Long-term efficacy and safety data with venetoclax-based combination therapy for older patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy
Optimal integration of venetoclax-based regimens into the care of older or unfit patients with newly diagnosed AML
Published efficacy and safety findings from the Phase III ASCERTAIN-AML study assessing oral decitabine/cedazuridine for patients with AML
Recent clinical trial data with the all-oral regimen of decitabine/cedazuridine with venetoclax for patients with AML who are ineligible for intensive induction
chemotherapy
Potential role of decitabine/cedazuridine, including as a component of all-oral up-front therapy
MODULE 2: Selection of Therapy for Younger Patients with AML without a Targetable Mutation; Promising Investigational Strategies — Dr Perl
Outcomes observed with standard intensive chemotherapy regimens for younger patients with unfavorable prognostic features, such as complex karyotype and TP53 mutation
Available findings with and ongoing investigation of venetoclax-based regimens for younger, fit patients with newly diagnosed AML; current role outside of a research setting
Activity, tolerability and current role, if any, of venetoclax-based regimens for younger patients with relapsed/refractory (R/R) AML
Rationale for targeting CD123 in AML; mechanism of action and structural components of pivekimab sunirine
Early data with pivekimab sunirine as monotherapy and ongoing evaluation as a component of combination regimens
Other promising investigational agents and strategies for patients with AML
MODULE 3: Role of FLT3 Inhibitors in AML Management — Dr Erba
Pharmacologic similarities and differences among available FLT3 inhibitors for AML; implications for potency, activity and tolerability
Principal findings from the Phase III QuANTUM-First study evaluating the addition of quizartinib to chemotherapy and continued as a single agent for patients with newly diagnosed AML with a FLT3-ITD mutation; FDA approval and current clinical role
Available data with the triplet combination of quizartinib with decitabine and venetoclax for AML with a FLT3-ITD mutation
Rationale for the ongoing Phase III QuANTUM-Wild trial evaluating quizartinib in combination with standard intensive induction and consolidation chemotherapy followed by single-agent quizartinib maintenance for AML without a FLT3-ITD mutation
Early data with gilteritinib combined with standard up-front therapy for FLT3-mutant AML
Major efficacy and safety data with gilteritinib as post-transplant maintenance for AML with a FLT3-ITD mutation; implications of minimal residual disease positivity for outcomes and potential clinical role of this strategy
Long-term outcomes reported with gilteritinib for patients with R/R AML with a FLT3 mutation; optimal incorporation in this setting
MODULE 4: Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Fathi
Mechanistic similarities and differences between available IDH1 (eg, ivosidenib, olutasidenib) and IDH2 (eg, enasidenib) inhibitors
Optimal integration of ivosidenib into the management of newly diagnosed and R/R IDH1-mutant AML
Major efficacy and safety findings with olutasidenib for R/R AML with an IDH1 mutation
FDA approval of olutasidenib and optimal integration into management algorithms
Early data with olutasidenib as maintenance therapy for patients with IDH1-mutant AML
Long-term data supporting the use of enasidenib for R/R IDH2-mutant AML; early data with and ongoing evaluation for patients with newly diagnosed disease
MODULE 5: Current and Future Role of Menin Inhibitors in the Treatment of AML — Dr Stein
Mechanism of action of menin inhibitors and rationale for their activity in patients with KMT2A-rearranged and NPM1-mutant AML
Published efficacy and safety data with revumenib among patients with R/R KMT2A-rearranged acute leukemias and NPM1-mutant AML in the Phase I/II AUGMENT-101 trial
Recent FDA approvals of revumenib for patients with R/R acute leukemias with a KMT2A translocation and those with R/R AML with NPM1 mutations; appropriate integration into the treatment paradigm for these populations
Key efficacy and safety findings from the Phase I/II KOMET-001 trial evaluating ziftomenib for R/R NPM1-mutant AML
Recent FDA approval and current role of ziftomenib for patients with NPM1-mutant AML
Biological rationale for, early research findings with and ongoing clinical trials of revumenib and ziftomenib in combination with other AML therapies
Available data with and ongoing evaluation of other menin inhibitors under development
Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).
Learning Objectives
Upon completion of this activity, participants should be able to
Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for primary and secondary AML to optimize clinical and quality-of-life outcomes.
Evaluate the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML, and appraise the current and potential role of this strategy.
Reflect on available research evidence with approved FLT3 inhibitors, and use this information to guide the clinical care of appropriately selected patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
Understand available efficacy and safety data with IDH1/2 inhibitors for patients with AML and an IDH1 or IDH2 mutation, and integrate these novel approaches into treatment algorithms.
Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with and the current and potential role of these novel agents.
Recall new data with agents and strategies currently under investigation for AML, and discuss ongoing trial opportunities with eligible patients.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
Dr Erba — Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Pharma America; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Aptose Biosciences Inc, Ascentage Pharma, Daiichi Sankyo Inc, Forma Therapeutics, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Kura Oncology, MacroGenics Inc, Novartis, Oryzon, PTC Therapeutics, Sumitomo Pharma America, Taiho Oncology Inc; Speakers Bureaus: AbbVie Inc, Bristol Myers Squibb, Incyte Corporation, Jazz Pharmaceuticals Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Study IRCs: AbbVie Inc (Chair, VIALE-A and VIALE-C); Study Steering Committee Chairs: Bristol Myers Squibb (AML Registry), Daiichi Sankyo Inc (QuANTUM-First and QuANTUM-Wild); Study Steering Committees: GlycoMimetics Inc, Kura Oncology, Sumitomo Pharma America; Nonrelevant Financial Relationships: Fortrea.
Dr Fathi — Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Kura Oncology, Pfizer Inc, Prelude Therapeutics, Remix Therapeutics, Rigel Pharmaceuticals Inc, Schrödinger, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, Thermo Fisher Scientific; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Kura Oncology, Servier Pharmaceuticals LLC.
Dr Lin — Consulting Agreements: Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Aptevo Therapeutics, Bio-Path Holdings Inc, Cardiff Oncology, CicloMed, Cleave Biosciences, Jazz Pharmaceuticals Inc, Kura Oncology, Lin BioScience; Data and Safety Monitoring Boards/Committees: Sumitomo Pharma America.
Dr Perl — Advisory Committees: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Johnson & Johnson, Rigel Pharmaceuticals Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals; Consulting Agreements: Astellas, Daiichi Sankyo Inc, Foghorn Therapeutics, Syndax Pharmaceuticals; Contracted Research: AbbVie Inc, Astellas, Daiichi Sankyo Inc, Syndax Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Foghorn Therapeutics; Nonrelevant Financial Relationships: Beat AML LLC.
Dr Stein — Consulting Agreements: AbbVie Inc, Astellas, Cullinan Therapeutics, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Contracted Research: Astellas, Bristol Myers Squibb, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Stock Options — Private Companies: Auron Therapeutics.
CONTRIBUTING CLINICAL INVESTIGATORS Jorge Cortes, MD — Consulting Agreements: Ascentage Pharma, Bio-Path Holdings Inc, Novartis, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, Terns Pharmaceuticals; Contracted Research: Ascentage Pharma, Bio-Path Holdings Inc, CytoAgents, Kura Oncology, Novartis, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Terns Pharmaceuticals; Stock Options/Stock — Public Companies: Bio-Path Holdings Inc.
Courtney D DiNardo, MD, MSCE — Advisory Committees: Astellas, Bristol Myers Squibb, Kura Oncology; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genmab US Inc, Molecular Partners, Rigel Pharmaceuticals Inc, Servier Pharmaceuticals LLC; Contracted Research: AbbVie Inc, Astex Pharmaceuticals, Auron Therapeutics, Remix Therapeutics, Rigel Pharmaceuticals Inc, Servier Pharmaceuticals LLC, SillaJen, SystImmune Inc.
Eunice S Wang, MD — Advisory Boards: AbbVie Inc, Blueprint Medicines, Cullinan Therapeutics, Daiichi Sankyo Inc, Dark Blue Therapeutics, Johnson & Johnson, Kite, A Gilead Company, Kura Oncology, Novartis, QIAGEN, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Schrödinger, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Kura Oncology, Menarini Group; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Gilead Sciences Inc; Speakers Bureaus: Astellas, Pfizer Inc, UpToDate.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas, Daiichi Sankyo Inc, Kura Oncology, and Rigel Pharmaceuticals Inc.
Directions
The Hyatt Regency Orlando hotel is connected by pedestrian bridges to the Orange County Convention Center, where the ASH Annual Meeting is taking place.
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia.
There is no registration fee for this event. For the in-person symposium in Orlando, preregistration (below) is required as seating is limited for this program.
NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting.
Thank you for your interest in our CME program. At this time online registration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 7:00 AM ET on Friday, December 5th. If you are interested in attending, please visit the registration desk outside the Regency Ballroom TUV (Convention Level) of the Hyatt Regency Orlando hotel (9801 International Drive).
Hyatt Regency Orlando is conveniently connected by pedestrian bridge to the Orange County Convention Center, where the 67th ASH Annual Meeting is taking place.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.
